A shared instrumentation core standardised its GH-axis reference set across three mechanisms for cross-PI use
A university analytical core holding GH-axis peptide standards for multiple PI groups needed a coherent reference set spanning both GHRH-analog and ghrelin-pathway mechanisms — with chirality verification on the D-amino-acid member and stable catalogue identity across re-orders. One qualification campaign locked the set into the core's SOP.
Published May 30, 2026 · Anonymized research-buyer story
GH-axis mechanisms standardised
2 (GHRH-analog + ghrelin)
Chirality verification
On COA for the D-residue member
Stability programme
12 months −20 °C per lot
Identity-drift complaints
0
Challenge
The core facility's Director maintained the GH-axis reference-standard inventory that several PI groups drew on for analytical-method validation and bioassay reagent qualification. The set spanned two mechanisms — GHRH-receptor analogs and a ghrelin-pathway secretagogue — and the mechanistic spread created a specific verification problem: the ghrelin-pathway pentapeptide member carries two D-amino acids and a C-terminal amide, so a mass check alone could not confirm its stereochemistry, yet the previous supplier's lot reports had documented it by intact mass only. On top of that, the supplier had twice changed the analytical-method-provenance language on the lot report and relabelled a SKU, which made the core's SOP reference to the standards' identity unreliable across multi-year audit windows. The Director needed a coherent GH-axis set, chirality verification on the D-residue member, consistent method-provenance language, and stable catalogue identity locked across re-orders.
Approach
Lyochem ran a one-time qualification campaign across the GH-axis SKUs the core identified for cross-PI use — the GHRH-analog members and the ghrelin-pathway pentapeptide — releasing each to the same packet template with consistent USP/EP/ICH method-provenance language on every release. For the pentapeptide member, the COA reported the chiral/configuration verification alongside the standard identity and purity data, so the stereochemistry that defines the molecule was documented rather than inferred from mass. Catalogue SKU identity was locked at the slug level so re-orders against the same SKU draw from the same documented synthesis route, and the 12-month −20 °C stability programme on every released lot covered the core's SOP refresh window. The Director and the core's analytical-chemistry liaison were given direct atelier contacts for lot-to-lot continuity questions.
Outcome
All the GH-axis SKUs cleared the core facility's qualification within a few weeks of first shipment, and the departmental SOP was updated to reference Lyochem catalogue slugs and the harmonised method-provenance language — including the chirality-verification line for the pentapeptide member. The SOP has run across refresh cycles without identity-drift complaints from the PI groups using the standards, and re-orders against the same SKUs continue to draw from the same documented route with the same per-lot data packet template.
“A GH-axis set is only coherent if the ghrelin-pathway member's stereochemistry is documented to the same standard as the GHRH analogs' sequences — a pentapeptide with two D-residues confirmed by mass alone is an identity gap a method reviewer will find. Lyochem put the chirality verification on the COA and locked the catalogue identity, which is exactly what an SOP that multiple PIs cite needs.”
